Search Results for “Novartis”

GlaxoSmithKline (GSK) announced that it has bought out Novartis’ stake in their joint consumer healthcare venture. GSK will now own 100 percent of the business

GlaxoSmithKline buys out Novartis’ stake in joint venture

$13bn acquisition will give GlaxoSmithKline full ownership of the over-the-counter healthcare business

Novartis scraps payout

Novartis buckles under political and shareholder pressure and scraps payment for consulting and non-compete agreement

Prescription for success: Emma Walmsley leads GSK transformation

After spending a decade lagging behind its peers, GSK named a new CEO in 2017. Despite having minimal experience in drug development, Emma Walmsley may well have turned out to be the lifeline the company needed

Shareholders have stopped acting as passive recipients of companies’ reports or obedient rubber-stampers of their plans and pay packages

Time for a boardroom reckoning

Shareholders are becoming increasingly vocal on a range of hot-topic issues. If boardrooms fail to address their concerns, business will inevitably suffer

Dr Jim Phillips

Midatech Pharma is proof that there is still a place in the pharmaceuticals market for smaller, more nimble companies. Under Jim Phillips’ leadership, the nanomedicine company has focused on niche products and accelerated growth through the strategic acquisition of complementary products and technologies. Aside from founding Talisker Pharma in 2004, Phillips has held senior positions […]

Midatech has a number of plans and a comprehensive strategy to build on its enviable position in the pharmaceutical market

Midatech prepares for strong growth in the pharmaceutical market

In a pharmaceutical industry dominated by sweeping M&A deals, smaller firms are finding success through agility and by identifying less saturated sections of the market

Astex Pharmaceuticals believes that open innovation in the pharmaceutical industry can invigorate internal research groups and inspire more strategic partnerships

Astex demonstrates the power of open innovation in pharma

Improved interactions between pharmaceutical companies and third parties have inspired some of the latest industry advances. Nowhere is this better illustrated than in the case of Astex

Midatech: on track to become a leading profitable biopharmaceutical company

The pharmaceutical industry is one that relies, above all, on innovation and new ideas. New ways of improving existing treatments are vital and valuable

New Jersey

Perfectly located and highly educated, it’s no surprise New Jersey is the state of choice for international companies looking to enter the US

The case for and against unconditional basic income in Switzerland

Growing wealth disparity in Switzerland has led to a referendum on an unconditional basic income, which could serve to narrow the gap

Problems for Big Pharma

The pharmaceutical industry could crumble as a number of patents on top-selling drugs are about to expire, which could cause a massive fall in profits

Joe Jimenez

With several sectors’ worth of experience under his belt, Jimenez has certainly proved to be the right man for Novartis

Daniel Vasella

While Vasella has overseen the production of some extremely effective products, his company has also experienced some of the biggest scandals in the past five years

Vectura results beat view; will up R&D by 10%

Inhaled-drug specialist Vectura Group posted a 29 percent rise in full-year revenue, helped by milestone payments from its partner Novartis, and said it had three new products in development. The British group is developing a generic steroid treatment for asthma and two speciality products: an inhaled anti-fungal treatment for lung-disease sufferers and a product to […]

German court overturns Glaxo’s patent on Advair

A German court ruled a key patent on GlaxoSmithKline Plc’s lung drug Advair is not valid, dealing a blow to the top-selling lung drug in Europe’s biggest market. Glaxo said on Thursday it would consider an appeal to a higher court, adding there were still obstacles to generic companies launching cheaper copies of the inhaled […]

Digital Editions